| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Legal and regulatory commentary |
| Population | Women |
| Source | FDA Law Blog (Hyman, Phelps & McNamara) |
| URL | thefdalawblog.com/2026/09/t-time-women-were-first-to-put-testosterone-back-on-fdas-agenda-now-its-industrys-turn (opens in a new tab) |
Specific Claim Evaluated
No FDA-approved testosterone product for women exists, and the FDA noted that the normal testosterone range in women is poorly defined, with assay variability.
Primary Research Supporting or Contradicting the Claim
The consensus statement finds direct assays highly unreliable in the female range and states that no blood level distinguishes women with and without sexual dysfunction (Davis et al., 2019).
Corrected Evidence-Based Interpretation
Accurate.
Rationale for Grade
The commentary reports the regulatory history and the measurement problems discussed at the workshop correctly. Its statements are consistent with consensus guidance. It does not make clinical benefit claims.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."